NCT03048942: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

NCT03048942
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have ER+ tumor(s)
Exclusions: Patients with symptomatic brain metastases confirmed with CT/MRI brain
https://ClinicalTrials.gov/show/NCT03048942

Comments are closed.

Up ↑